C. Eaton

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Clinical Cancer Research.

A Phase I Single Ascending Dose Study Of NKTT120 In Stable Adult Sickle Cell Patients

R. Mashal, K. Ataga, C. Eaton, 2013 .

Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

T. Mikkelsen, E. Wong, D. Schiff, 2010 .

NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial

K. Ataga, E. Vichinsky, C. Eaton, 2014 .

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

W. K. Henry, C. Crumpacker, H. Balfour, 1996, Antimicrobial agents and chemotherapy.

Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV‐positive patients

M. Polis, G. Drusano, M. Jacobson, 1996, AIDS.